drugset / Trial / NCT01254045

Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome

NCT01254045 ↗

Phase 2 Completed 10 enrolled Stanford University
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether the medication oxytocin is an effective and tolerable treatment in adolescent males with fragile X syndrome (FraX) for improving socially appropriate behaviors and reducing social anxiety.

Timeline

Start
2007-02
Primary completion
2009-11
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxytocin Peptide 24 iu Intranasal
Subject Oxytocin Peptide 48 iu Intranasal

Indications